Audit: QRS - Colostrum for Health & Longevity

Audit conducted on 19/09/2026 01:54 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol doses (ER 344, 348, 350, 358), time-to-effect (ER 403, 182), benefit/risk tier headings (ER 154–208, 234–276), contraindications (ER 316–322), interactions (ER 300–312), monitoring table (ER 437–443), cadence (ER 433), qualitative markers (ER 447–451).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s hedges are carried through, e.g. marker_2_target “No established target; change from baseline” mirrors ER 443.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and breastfeeding” remains under Contraindications, not Key Interactions; immunosuppression keeps its “unless the product is documented as heat-treated” condition.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from ER “Populations who should avoid Colostrum”; Key Interactions from the ER interaction bullets; risks from Potential Risks & Side Effects. No modifying factor is promoted to a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, NCT identifiers, investigator names or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s sober, gap-aware framing (dose mismatch, local-gut-only action).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits/risks plus concrete doses, thresholds and markers give the reader an actionable, non-alarmist basis.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	States what trials used and what products supply rather than issuing instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Interaction rows state separations as facts (“two-hour separation”), not directives.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells report “the dominant protocol” and “the most common recommendation” descriptively.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Acronyms are spelled out in full: “immunoglobulin G”, “insulin-like growth factor 1”, “estimated glomerular filtration rate”, “World Anti-Doping Agency”, “Non-steroidal anti-inflammatory drugs”, “Proton pump inhibitors”.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, tier line and table cell is a trimmed fragment; no sentences carry mechanism or citations.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Research-dose range, batch certification and a seven-marker panel address a proactive reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, fasted morning timing, sub-60 °C liquid and 2–4 hour drug separations are retained.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes access to fecal calprotectin, sugar-probe permeability testing and serum IGF-1.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance names the consumer-dose gap explicitly, which is the decisive point for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“Oral antibiotics”, “Oral iron supplements”, “empty stomach”, “Serum immunoglobulin A” — no lay route-of-administration wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at QRS 445, 490, 538, 624, 649, 750, 567, 587, 653–655; tier labels appear unchanged in both Benefits and Risks.
3.2	All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS.	🟢	Extracted and compared both span sets: every template name is present, with marker_#_* expanded to marker_1–7 and qualitative_item_# expanded to qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The <style> block is byte-identical to the template (whitespace-normalised md5 match), and the website="evidence_review", website="audit" and website="full_review" spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard research dose”, “Split dosing”, “Best time of day” and all seven interaction labels match the ER bold labels (ER 344, 348, 350, 300–312).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Only the parenthetical gloss “— bone-density drugs” is trimmed from the bisphosphonate label, which 9.4/9.5 explicitly require; drug names are retained.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode emoji scan over the file returns no matches; tiers are rendered with <strong> labels and CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each section is condensed to key facts (no mechanism, no effect sizes, no citations) while still carrying the counts mandated by 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	QRS 2–14: the comment opens on line 2, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the caption text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required by the colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	QRS 4: er_filename: colostrum_2026-0919-0012_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	QRS 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	QRS 6: qrs_creation_date: 2026-0919-0107.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	QRS 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	QRS 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	QRS 9: qrs_filename: colostrum_2026-0919-0012_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	QRS 22: Colostrum for Health & Longevity - Quick Reference Sheet.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	QRS 417: Colostrum for Health & Longevity, matching ER frontmatter line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	QRS 421: 09/19/2026, from qrs_creation_date: 2026-0919-0107.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	QRS 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	QRS 434–437 condenses ER 473–479: local gut action, the two holding benefits, the conflicted claims, the dose gap and the harms.
7.2	[at_a_glance] is no longer than 60 words	🟢	52 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Digestion/gut locality ER 473; illness days and diarrhoea ER 475; muscle/skin/hair ER 475; dose gap ER 479; allergens and contamination ER 477.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain wording throughout (“dried cow’s first milk”, “cold-like symptom days”, “milk allergens”); no acronyms or evidence-grade labels.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author or year is named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers, ratios or confidence intervals appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER “Populations who should avoid Colostrum” list (ER 316–322).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-populations are present; none invented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	QRS 570–582: seven discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Explanatory tails are stripped, e.g. ER “Pregnancy and breastfeeding, where safety and efficacy data are lacking” → “Pregnancy and breastfeeding”; no dash-trailing clause survives.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m²) on a protein-restricted diet” keeps the staging, threshold and diet condition; “of any severity”, “unless … heat-treated” and “unless the preparation is lactose-reduced” are retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –>	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to ER bullets 300–312.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER’s immunosuppressant bullet (ER 298) is correctly omitted because active immunosuppression is already a Contraindication (QRS 572). The remaining seven ER interactions are all present.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	QRS 590–614: seven discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to label plus outcome (“two-hour separation”, “four-hour separation”, “additive benefit”); the ER’s calcium-binding and gastric-pH mechanisms are dropped, as is the “— bone-density drugs” gloss.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists are retained for antibiotics, bisphosphonates, proton pump inhibitors, NSAIDs and gut-barrier supplements; the separation windows (two-hour, four-hour) are preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –>	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets (ER 344, 348, 350, 358).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dosing frequency and timing are the three decisive implementation choices; the consumer-dose gap is folded into action_1_sub rather than consuming a cell.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects, and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; no placeholder remains anywhere in the file.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Illness days (ER 403), gut permeability (ER 403) and the eight-week strength/bone result (ER 182) are the ER’s only quantified onset timings.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Illness days is the High-tier benefit and comes first; gut permeability and strength/bone are both Medium-tier and follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; values “8–12 weeks”, “Days to 2 weeks” and “8 weeks” match the ER verbatim in substance.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 403), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed benefit corresponds to an ER Expected Benefits sub-heading (ER 154–208).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at QRS 540, 546, 552, 555 with the matching ER tier content.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Tier lines are semicolon-separated headline phrases only; the ER’s magnitudes (rate ratio 0.56, +1.49 kg, +24 kg) and “⚠️ Conflicted” markers are all stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every listed risk corresponds to an ER Potential Risks & Side Effects sub-heading (ER 234–276).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at QRS 626, 629, 632, 638 with the matching ER tier content.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	“Digestive intolerance”; “Raised insulin-like growth factor 1 and anti-doping uncertainty; heavy metals; pathogens in raw product” — the ER’s 5–10% prevalence and 72-sample survey figures are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any risks span; the ER’s anaphylaxis gloss and contamination sample counts are absent.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets and rationales all trace to the ER biomarker table (ER 437–443).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER biomarkers present: fecal calprotectin, urinary lactulose/rhamnose ratio, high-sensitivity C-reactive protein, serum insulin-like growth factor 1, serum immunoglobulin A, complete blood count with differential, 25-hydroxyvitamin D.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS 743: “Baseline fasted, then 8 weeks, 6 months, annually; insulin-like growth factor 1 once at 8 weeks.” matches ER 431–433.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s “Qualitative markers to track alongside the laboratory values” list (ER 447–451).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present: symptom days per season, bloating/stool form/post-meal discomfort, food tolerance, recovery time between hard sessions, afternoon energy and illness interruption.

Issues 19/09/2026 01:54

Pass rate 100.00%. No issues found.

Issues 19/09/2026 01:46

1. 1.1 — IgA marker rationale invented: [marker_5_why] at line 713 states “Selective deficiency shrinks the mucosal response”, but the ER says only that deficiency “changes the expected size of the mucosal response” (ER line 440) and elsewhere that low-IgA people “have the most to gain” (ER line 219), so the asserted direction is unsupported.

Fixes 19/09/2026 01:46

1. 1.1 — IgA marker rationale corrected: [marker_5_why] changed from “Selective deficiency shrinks the mucosal response” to “Selective deficiency changes the expected mucosal response”, matching the ER’s neutral wording.

Issues 19/09/2026 01:40

1. 1.2 / 1.3 — ER hedges dropped, claims strengthened: Three ER hedges are lost: the proton pump interaction reads “more effect, more digestive symptoms” (QRS line 600) where the ER says it “may increase both effect and digestive symptoms”; the protocol sub reads “Liquid below 60 °C only” (QRS line 484) where the ER says manufacturers specify “below about 60 °C”; and the lede says muscle, skin and hair claims “do not” hold up (QRS line 436) where the ER Conclusion says they are “either conflicted or untested”.

Fixes 19/09/2026 01:40

1. 1.2 / 1.3 — ER hedges restored: The proton pump inhibitor item now reads “may increase effect and digestive symptoms” instead of “more effect, more digestive symptoms”; the protocol sub now reads “Liquid below about 60 °C only”; and the lede now reads “muscle, skin and hair claims are conflicted or untested” instead of “claims do not”, matching the ER Conclusion.

Issues 19/09/2026 01:36

1. 2.7 — Unexpanded eGFR acronym: The chronic kidney disease contraindication (line 579) carries the bare acronym “eGFR”, the only unexpanded acronym on a sheet that otherwise spells out “immunoglobulin G”, “insulin-like growth factor 1”, “World Anti-Doping Agency” and “Non-steroidal anti-inflammatory drugs” in full.
2. 4.5 — Sheet overruns one A4 page: The three [action_#_sub] cells (lines 456, 470, 484) each run 109–116 characters and wrap to three or four lines, [monitoring_cadence] (line 764) and most Monitoring “Target”/”Why” cells wrap to a second line, and four [stop_items] (lines 573–582) wrap to two or three lines, pushing the populated sheet well past the one-page budget instead of being condensed to it.

Fixes 19/09/2026 01:36

1. 2.7 — Unexpanded eGFR acronym: Expanded the bare acronym in the chronic kidney disease contraindication to the ER’s own wording, from “(eGFR below 30 mL/min/1.73 m²)” to “(estimated glomerular filtration rate below 30 mL/min/1.73 m²)”.
2. 4.5 — Protocol sub-cells condensed: Trimmed all three [action_#_sub] cells to fit the protocol row budget, e.g. “Standardised to 10–20% immunoglobulin G, giving 2–12 g of antibody daily. Most products supply only 1–6 g/day.” became “10–20% immunoglobulin G gives 2–12 g of antibody daily; most products supply 1–6 g/day.”
3. 4.5 — Monitoring cells condensed: Shortened [marker_1_why] to “Gut wall inflammation; room to benefit”, [marker_2_target] to “No established target; change from baseline” and [monitoring_cadence] to drop the redundant “rechecked”, keeping every biomarker, target and rationale.
4. 4.5 — Gate items condensed: Tightened two contraindications (“who cannot obtain a batch-certified product” to “without a batch-certified product”; “unless using a lactose-reduced preparation” to “unless the preparation is lactose-reduced”) and one interaction (“more effect and more digestive symptoms” to “more effect, more digestive symptoms”), with all seven items in each gate retained.

Issues 19/09/2026 01:27

1. 4.5 — QRS overruns one A4 page: At the template’s print geometry (A4 less 12 mm .sheet padding, ~1030 px of usable height) the populated sheet runs roughly 1.8–1.9 pages; the Key Interactions gate (lines 594-620), the seven-row Monitoring table (lines 665-772), the Protocol and Time-to-effect sub-lines (lines 455-458, 469-472, 483-486, 503-506) and the Qualitative Assessment list (lines 787-815) all carry full-sentence prose rather than being condensed to a per-section budget.

Fixes 19/09/2026 01:27

1. 4.5 — Condensed sections to page budget: Condensed the at-a-glance lede (57 → 50 words), all three Protocol and all three Time-to-effect sub-lines, the Benefits High/Medium and Risks Low entries, four Key Interaction items, every Monitoring “Why” cell plus the insulin-like growth factor 1 and complete blood count targets, the monitoring cadence and the two longest Qualitative Assessment items, cutting roughly 17% of the sheet’s prose. All seven contraindications, seven interactions, seven biomarkers and five qualitative markers were kept, so the sheet still exceeds one A4 page on the condensed content that items 8.2, 9.2, 14.2 and 15.2 require it to carry.

Issues 19/09/2026 01:19

1. 9.2 — PPI interaction has no content: The proton pump inhibitor item at line 604 is <strong>Proton pump inhibitors (omeprazole, esomeprazole)</strong> with nothing after it, dropping the ER’s “Monitor” classification and its stated effect (more intact immunoglobulin reaching the intestine, increasing both effect and digestive symptoms), unlike every other interaction item which pairs its label with a key fact.

Fixes 19/09/2026 01:19

1. 9.2 — PPI interaction had no content: Added the ER’s key fact to the proton pump inhibitor item, changing <strong>Proton pump inhibitors (omeprazole, esomeprazole)</strong> to <strong>Proton pump inhibitors (omeprazole, esomeprazole):</strong> may increase both effect and digestive symptoms, bringing it into line with the other interaction items.

Issues 19/09/2026 01:14

1. 1.3 — Contraindication broadened beyond ER: Line 578 reads “Competitive athletes who cannot obtain a batch-certified product”, dropping the ER’s limiting qualifier “under World Anti-Doping Agency jurisdiction” (ER 319) and widening the gate to all competitive athletes.
2. 2.5 / 2.6 / 2.9 — Imperative in Key Interactions: The antibiotics item at line 594 instructs the reader — “separate by at least two hours” — instead of stating the fact as the ER does (“The usual mitigation is a separation of at least two hours”, ER 300) and as the sibling items do (“two-hour separation”, line 600).

Fixes 19/09/2026 01:14

1. 1.3 — WADA qualifier restored to gate: The athlete contraindication now reads “Competitive athletes under World Anti-Doping Agency jurisdiction who cannot obtain a batch-certified product”, matching the ER instead of applying to all competitive athletes.
2. 2.5 / 2.6 / 2.9 — Imperative removed from interactions: The antibiotics interaction was changed from the instruction “separate by at least two hours” to the statement “separation of at least two hours”, in line with the ER wording and the sibling items.